Navigation Links
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Date:11/16/2007

WILMINGTON, Del., Nov. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for maintenance treatment of schizophrenia in adult patients. On May 17, 2007, the FDA approved SEROQUEL XR for the acute treatment of schizophrenia in adult patients.

Schizophrenia patients experience high rates of symptom relapse, and as a result, there is an important need for long-term treatment options for schizophrenia to help reduce the risk of the recurrence of acute psychotic episodes. (1,2)

In the clinical trial supporting this approval, patients with schizophrenia who were treated with SEROQUEL XR experienced a significantly longer time to relapse, compared with patients receiving placebo. Patients receiving SEROQUEL XR demonstrated an 84% reduction in the relative risk of relapse (hazard ratio 0.16; p<0.0001). Results showed the estimated risk of relapse after six months was 14.3% in the SEROQUEL XR group versus 68.2% in the placebo group (p<0.0001). Differences in relapse rate between active treatment and placebo were large enough to require the study to be stopped early. The complete results of the clinical trial appear in the November issue of the journal Psychiatry 2007.(3)

"Today's FDA approval helps address the need for longer-term treatment options for patients with schizophrenia," said Mark Scott, Ph.D., Executive Director for Development, AstraZeneca. "The clinical trial results provided compelling evidence for reducing the risk of relapse when these patients are treated with SEROQUEL XR."

Schizophrenia is a serious brain disorder with symptoms including distorted perceptions of reality, hallucinations and delusions, illogical thinking, and flat or blunted emotions, affecting over 2 million American adults -- about 1% of the population 18 years and older.(4,5)

The FDA approval for main
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amedicald...ydisruptivesurgicaltreatmentsforthespine,announced...r30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferencecall...theCompany,sproductsandwillincludecommentsfrommana...dial-innumbersare1-877-407-4018fordomesticcallersa...
(Date:11/25/2009)...-Reportlinker.comannouncesthatanewmarketresearchre...ugDelivery-USMarketTrends&Analysis http://www...y---US-Market-Trends--Analysis.html ,, TheUSin...ftherapeuticapplicationsfromthedeliveryofconventio...rapeuticdrugs.Thefutureofthetechnologyhingesontoth...
(Date:11/25/2009)...PRNewswire/-- ChemoCentryx,Inc.,announcedtodaytha...theProspectiveRandomizedOralTherapyEvaluationinCro...entswithmoderate-to-severeCrohn,sdiseasedemonstrat...ityprofile.Thestudydemonstratedevidenceofclinicale...70-pointdecreaseintheCrohn,sDiseaseActivityIndex(C...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Trubion Announces Positive Data From a Phase 1 2 Study of TRU 016 for the Treatment of Chronic Lymphocytic Leukemia 28CLL 29 4498 1Trubion Announces Positive Data From a Phase 1 2 Study of TRU 016 for the Treatment of Chronic Lymphocytic Leukemia 28CLL 29 4498 2Trubion Announces Positive Data From a Phase 1 2 Study of TRU 016 for the Treatment of Chronic Lymphocytic Leukemia 28CLL 29 4498 3Trubion Announces Positive Data From a Phase 1 2 Study of TRU 016 for the Treatment of Chronic Lymphocytic Leukemia 28CLL 29 4498 4Trubion Announces Positive Data From a Phase 1 2 Study of TRU 016 for the Treatment of Chronic Lymphocytic Leukemia 28CLL 29 4498 5Heart Disease Treatment Breakthrough 4495 1Heart Disease Treatment Breakthrough 4495 2Heart Disease Treatment Breakthrough 4495 3TNFerade 28TM 29 Phase III Data Presented at ASCO 4493 1TNFerade 28TM 29 Phase III Data Presented at ASCO 4493 2TNFerade 28TM 29 Phase III Data Presented at ASCO 4493 3
...ew released today by HHS, Agency for Healthcare Re...fit is lacking for many common ways of,treating os...y supplement,ingredients, a common surgical proced...that glucosamine and chondroitin, over-the-counter...ly because of their,purported benefits to relieve ...
...ty of America (IDSA) 45TH ..., Inc. today announced,results from two important ...Society of America (IDSA) 45th Annual Meeting addi...ytial virus (RSV). RSV is a viral,pathogen that pr...pring.,While RSV typically manifests cold-like sym...
Other Medicine Technology:Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee 2MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results 2MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results 3MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results 4
(Date:11/25/2009)...were treated with cisplatin-based chemotherapy had...side effects and Raynaud-like phenomena, than men ...to a new study published online November 25 in the...arianne Brydy, M.D., of the Department of Oncology..., and colleagues conducted a cross-sectional study...
(Date:11/25/2009)...w definite conclusions, experts say, , ,...ic patients with blocked coronary arteries, there ...r whether patients undergo bypass surgery or angio..., Bypass surgery has been the standard treatmen...se. However, less invasive approaches such as angi...
(Date:11/25/2009)...s, study finds , , WEDNESDAY, Nov. 25 (...mong the potential problems faced by long-term sur...cisplatin-based chemotherapy, a new study has foun...ated for unilateral testicular cancer between 1980...ucted from 1998 to 2002. , The researchers foun...
(Date:11/25/2009)...htYear ,, WASHINGTON,Nov.25/PRNewswire-USNews...ssuedthe 4thAnnualReportCardonLungCancer .ThisRepo...aldiseaseinthestateofGeorgia.LCA-GAisachapterofLun...dicatedexclusivelytopatientsupportandadvocacyforpe...http://www.newscom.com/cgi-bin/prnh/20081016/LCALO...
(Date:11/25/2009)... cells, study finds , , WEDNESDAY, Nov. ...in a fingernail-size implant eliminated melanoma t...d uses polymer disks, 8.5 millimeters in diameter,...implanted under the skin to reprogram the immune s...entists who developed the implant predicted that i...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...ree condoms for nearly 9 months will soon be provi.../ the New York city logo as a promotional offer. M...uted since June, according to health officials. ...r would materialise in the next couple of months. ...
...cted that by 2020 road accidents will be the third...c health issues like tuberculosis, diarrhoea and H...atalities are expected to increase from 135,000 in...n' released Tuesday. Around 85 percent of th...
...tival, hot air balloon festival for 2 weeks, inaug...as been the joint efforts of Rajasthan Tourism and...ling from 11countries are participating, who will ... hot air balloons, the locale of Rajasthan making ...
...on has been confirmed in Greece, Bulgaria and Sl...ve been initiated by the Italian following detecti... br> The EU confirmed that samples sent to its ...eece. A spokesman said that in keeping with E...
...ll condoms in school through installation of condo... largest political party in Australia.// Ka... Australia's state parliament, said the issue was ...they are certainly telling their friends. We can't...
...riage) is thought to bring an increased number of ...ge lead to betterment in the health of both sexes ...y couples also offer numerous advantages. Prof...alth said that such marriages apart from health be...
Other Medicine News:Health News:Road accidents greater threat than AIDS, TB: WHO 2
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: